solver.press

Computational equilibrium strategies can predict optimal drug combinations to overcome evolutionary trade-offs in antibiotic resistance.

BiologyMay 19, 2026Evaluation Score: 65%

Adversarial Debate Score

66% survival rate under critique

Model Critiques

openai: The hypothesis is falsifiable and supported by the literature indicating that evolutionary trade-offs exist and can be modeled computationally, but direct evidence that equilibrium strategies can reliably predict optimal drug combinations is limited; compensatory mutations and ecological complexi...
mistral: The hypothesis is falsifiable and aligns with evidence on evolutionary trade-offs in resistance, but counterarguments (e.g., compensatory mutations, environmental variability) weaken its predictive power without further empirical validation.
google: Falsifiable and supported by the papers, but "optimal" is hard to define and achieve in a complex evolutionary system. The hypothesis could be strengthened by specifying the type of computational equilibrium strategies and the criteria for optimality.
anthropic: ** The hypothesis is falsifiable in principle and is supported by empirical evidence that evolutionary trade-offs exist and can be exploited, but the papers provide only foundational biological observations rather than direct validation of computational equilibrium strategies predicting *optimal...
grok: Hypothesis is falsifiable via targeted experiments comparing predicted vs. observed resistance trajectories, and papers confirm trade-offs exist that could be exploitable; however, compensatory mutations and ecological complexity noted in several excerpts weaken direct predictive power without ad...

Supporting Research Papers

Formal Verification

Z3 logical consistency:✅ Consistent

Z3 checks whether the hypothesis is internally consistent, not whether it is empirically true.

Experimental Validation Package

This discovery has a Claude-generated validation package with a full experimental design.

Precise Hypothesis

Computational equilibrium strategies (specifically evolutionary game theory and Nash equilibrium modeling) can identify drug combinations that exploit collateral sensitivity trade-offs in antibiotic-resistant bacterial populations, such that the predicted combinations achieve ≥2-fold greater reduction in minimum inhibitory concentration (MIC) compared to empirically selected combinations in ≥70% of tested resistant strains, and suppress resistance evolution by ≥50% over 30-day serial passage experiments relative to standard-of-care combinations.

Disproof criteria:
  1. Computationally predicted combinations achieve <1.2-fold MIC reduction compared to randomly selected combinations in ≥3 independent bacterial species tested.
  2. Resistance suppression rate of predicted combinations is statistically indistinguishable (p > 0.05, two-tailed t-test) from empirically chosen combinations in serial passage experiments across ≥5 strain replicates.
  3. Nash equilibrium solutions fail to converge or produce degenerate solutions (all strategies equivalent) in ≥40% of tested drug-pair fitness landscapes.
  4. Predicted "evolutionarily stable" combinations are overcome by resistance within 15 days in ≥60% of serial passage replicates.
  5. Model predictions show Pearson correlation r < 0.4 between predicted and observed collateral sensitivity coefficients across a held-out test set of ≥20 drug pairs.
  6. Independent replication in ≥2 external laboratories fails to reproduce primary findings with effect sizes within 25% of original estimates.

Experimental Protocol

Phase 1 — Computational Model Construction (Days 1–30): Build evolutionary game theory models using empirical fitness landscapes from published collateral sensitivity datasets. Parameterize payoff matrices for pairwise drug interactions. Compute Nash equilibria and evolutionarily stable strategies (ESS) for drug cycling and combination schedules.

Phase 2 — In Vitro Validation (Days 31–90): Test top-5 computationally predicted combinations vs. top-5 empirically selected combinations vs. single-drug controls in E. coli K-12 MG1655 and clinical ESKAPE pathogen isolates (minimum n=3 species, n=6 strains each). Measure MIC, kill curves, and resistance emergence via serial passage (30 days, daily transfer at sub-MIC concentrations).

Phase 3 — Mechanistic Verification (Days 91–120): Whole-genome sequencing of evolved populations at days 0, 10, 20, 30. Quantify mutation frequency, identify resistance mutations, and verify that predicted trade-off loci are under selection as modeled.

Phase 4 — Predictive Generalization (Days 121–150): Apply trained model to 3 novel drug pairs not used in training. Assess prediction accuracy on held-out data. Compute ROC-AUC for binary classification of "effective vs. ineffective" combinations.

Required datasets:
  1. CARD (Comprehensive Antibiotic Resistance Database) v3.2+: resistance gene annotations and mutation data for model parameterization.
  2. PATRIC/BV-BRC bacterial genomics database: fitness landscape data for ≥500 antibiotic-resistant isolates.
  3. Collateral sensitivity datasets: Imamovic & Sommer (2013), Lázár et al. (2014), Barbosa et al. (2019) — pairwise MIC matrices for ≥20 antibiotic pairs in E. coli.
  4. EUCAST/CLSI MIC breakpoint tables for all tested antibiotics.
  5. PK/PD parameter database (e.g., DrugBank, literature) for 20 candidate antibiotics.
  6. Experimental fitness landscape: generate in-house checkerboard MIC assays for ≥10 drug pairs × 6 strains = 60 fitness matrices (minimum viable dataset).
  7. Whole-genome sequencing data: Illumina short-read WGS for evolved populations (estimated 180 samples × 5M reads each).
  8. Validated game-theory software: EGTtools, Nashpy, or custom Python implementation with unit-tested Nash solver.
Success:
  1. Primary: Predicted combinations achieve ≥2-fold greater MIC reduction vs. empirical combinations in ≥70% of tested strains (p < 0.05, paired t-test, n=18 per group).
  2. Resistance suppression: ≥50% reduction in resistance emergence rate (Kaplan-Meier log-rank p < 0.01) over 30-day serial passage.
  3. Model accuracy: Pearson r ≥ 0.65 between predicted and observed collateral sensitivity coefficients on held-out test set (n ≥ 20 drug pairs).
  4. Generalization: ROC-AUC ≥ 0.75 for synergy prediction on 3 novel held-out drug pairs.
  5. Mechanistic: ≥80% of resistance mutations in serial passage populations occur at loci predicted by the model's trade-off structure.
  6. Reproducibility: Effect sizes within 30% of primary estimates when replicated in ≥1 external laboratory.
Failure:
  1. MIC fold-change for predicted combinations < 1.2× vs. empirical combinations (below meaningful clinical threshold).
  2. Resistance emergence rate not significantly different between predicted and comparator combinations (log-rank p > 0.05).
  3. Model Pearson r < 0.4 on held-out collateral sensitivity data.
  4. Nash equilibrium solver fails to find unique solutions in >40% of fitness landscapes tested.
  5. WGS reveals resistance mutations predominantly at loci not captured in model (>60% unexplained mutations).
  6. Serial passage populations overcome predicted combinations within 10 days in >50% of replicates.
  7. Computational predictions perform no better than random drug pair selection (ROC-AUC ≤ 0.55).

120

GPU hours

150d

Time to result

$28,000

Min cost

$185,000

Full cost

ROI Projection

Commercial:
  1. Diagnostics: Companion diagnostic platform to identify patient-specific collateral sensitivity profiles from clinical isolate WGS ($500–2,000 per test; addressable market ~5M resistant infection cases/year in US/EU = $2.5–10B market).
  2. Software licensing: Equilibrium strategy prediction software licensed to hospital systems and pharmaceutical companies ($50,000–500,000/year per enterprise license; 100 major hospital systems = $5–50M/year recurring revenue).
  3. Pharmaceutical partnerships: Co-development agreements with antibiotic manufacturers to optimize combination regimens for existing drug portfolios; estimated deal value $10–50M per partnership.
  4. Biodefense: BARDA/DARPA funding interest for biodefense applications (engineered pathogen resistance management); potential $20–100M in government contracts.
  5. Veterinary medicine: Agricultural antibiotic resistance management (AMR in livestock is $2B/year problem); adaptation of platform for veterinary use adds significant addressable market.
  6. Academic licensing: Open-source computational tools with premium support contracts for academic medical centers.

🔓 If proven, this unlocks

Proving this hypothesis is a prerequisite for the following downstream discoveries and applications:

  • 1adaptive-drug-cycling-protocols-clinical-implementation
  • 2personalized-antibiotic-regimen-optimization-patient-genomics
  • 3evolutionary-trap-design-multidrug-resistant-tuberculosis
  • 4game-theory-antifungal-combination-resistance-suppression
  • 5in-vivo-pharmacodynamic-validation-equilibrium-drug-strategies

Prerequisites

These must be validated before this hypothesis can be confirmed:

Implementation Sketch

# Evolutionary Game Theory Drug Combination Optimizer
# Architecture Overview

## MODULE 1: Data Ingestion & Preprocessing
class CollateralSensitivityLoader:
    def load_mic_data(sources=["CARD", "PATRIC", "literature_csv"]):
        # Returns: DataFrame[strain_id, drug_A, drug_B, MIC_A, MIC_B, 
        #                     MIC_A_after_resistance_to_B, MIC_B_after_resistance_to_A]
        pass
    
    def compute_collateral_coefficient(mic_baseline, mic_after_resistance):
        # CS_coeff = log2(MIC_after / MIC_baseline)
        # Negative = collateral sensitivity, Positive = cross-resistance
        return np.log2(mic_after_resistance / mic_baseline)
    
    def build_payoff_matrix(drugs: List[str], strains: List[str]):
        # Shape: [n_drugs × n_drugs × n_strains]
        # payoff[i,j,k] = fitness of bacteria resistant to drug_i when exposed to drug_j in strain_k
        pass

## MODULE 2: Nash Equilibrium Solver
class EvolutionaryEquilibriumSolver:
    def __init__(self, payoff_matrix: np.ndarray):
        self.payoff = payoff_matrix  # [n_strategies × n_strategies]
        self.game = nashpy.Game(payoff_matrix, -payoff_matrix)  # zero-sum approximation
    
    def find_nash_equilibria(self):
        # Use support enumeration for exact solutions
        equilibria = list(self.game.support_enumeration())
        return equilibria  # List of (sigma_row, sigma_col) mixed strategy pairs
    
    def check_ess(self, strategy: np.ndarray, epsilon=0.01):
        # ESS condition: f(s,s) > f(s_mutant, s) for all mutants
        # Returns: bool, stability_score (float)
        for mutant in self.generate_mutant_strategies(strategy, epsilon):
            if self.fitness(mutant, strategy) >= self.fitness(strategy, strategy):
                return False, 0.0
        return True, self.compute_stability_margin(strategy)
    
    def rank_combinations(self, equilibria):
        # Score = ESS_stability × collateral_sensitivity_coefficient
        # Returns: ranked list of drug combinations
        pass

## MODULE 3: Experimental Design Generator
class ExperimentalDesigner:
    def select_top_combinations(ranked_combinations, n=5):
        # Returns top-N combinations for wet lab validation
        pass
    
    def generate_checkerboard_layout(drug_A, drug_B, conc_range):
        # 8×8 96-well plate layout for MIC checkerboard
        # Returns: plate_map DataFrame
        pass
    
    def design_serial_passage_schedule(combinations, days=30):
        # Daily transfer protocol with MIC measurement schedule
        pass

## MODULE 4: Statistical Analysis Pipeline
class ValidationAnalyzer:
    def compute_fici(mic_A_alone, mic_B_alone, mic_A_combo, mic_B_combo):
        return (mic_A_combo / mic_A_alone) + (mic_B_combo / mic_B_alone)
        # FICI < 0.5: synergy, 0.5-4.0: indifference, >4.0: antagonism
    
    def kaplan_meier_resistance_emergence(time_to_4fold_mic_increase):
        # Returns: survival curve, log-rank p-value vs. comparator
        from lifelines import KaplanMeierFitter
        pass
    
    def model_calibration(predicted_cs_coefficients, observed_cs_coefficients):
        pearson_r, p_value = scipy.stats.pearsonr(predicted, observed)
        brier_score = sklearn.metrics.brier_score_loss(binary_labels, predicted_probs)
        return pearson_r, brier_score
    
    def roc_analysis(predicted_scores, true_synergy_labels):
        auc = sklearn.metrics.roc_auc_score(true_synergy_labels, predicted_scores)
        return auc

## MODULE 5: WGS Analysis Pipeline (Snakemake workflow)
# Rule 1: FastQC quality control
# Rule 2: BWA-MEM2 alignment to reference genome
# Rule 3: GATK HaplotypeCaller variant calling
# Rule 4: CARD RGI resistance gene annotation
# Rule 5: Compute mutation frequency at predicted trade-off loci
# Rule 6: Compare observed vs. predicted resistance mutation spectrum

## MAIN EXECUTION FLOW:
if __name__ == "__main__":
    # 1. Load and preprocess data
    data = CollateralSensitivityLoader.load_mic_data()
    payoff_matrices = data.build_payoff_matrix(drugs=DRUG_LIST, strains=STRAIN_LIST)
    
    # 2. Solve for equilibria per strain
    all_predictions = {}
    for strain in STRAIN_LIST:
        solver = EvolutionaryEquilibriumSolver(payoff_matrices[:,:,strain])
        equilibria = solver.find_nash_equilibria()
        ess_combinations = [(e, solver.check_ess(e)) for e in equilibria]
        all_predictions[strain] = solver.rank_combinations(ess_combinations)
    
    # 3. Aggregate predictions across strains (consensus ranking)
    consensus = aggregate_cross_strain_predictions(all_predictions)
    top5 = ExperimentalDesigner.select_top_combinations(consensus, n=5)
    
    # 4. Generate experimental protocols
    protocols = ExperimentalDesigner.design_serial_passage_schedule(top5)
    
    # 5. [WET LAB PHASE - external]
    
    # 6. Analyze results
    results = ValidationAnalyzer.compute_fici(experimental_data)
    survival = ValidationAnalyzer.kaplan_meier_resistance_emergence(passage_data)
    calibration = ValidationAnalyzer.model_calibration(predicted, observed)
    auc = ValidationAnalyzer.roc_analysis(scores, labels)
    
    # 7. Report
    generate_validation_report(results, survival, calibration, auc)
Abort checkpoints:
  1. DAY 7 — Data Quality Check: If <60% of curated MIC data points pass quality filters (CV < 20% across replicates, complete drug-strain coverage), abort and expand data collection before proceeding. Estimated cost saved by early abort: $15,000–40,000.
  2. DAY 14 — Nash Solver Validation: If Nash equilibrium solver fails to find unique solutions in >40% of synthetic benchmark games (with known analytical solutions), abort computational phase and redesign solver architecture. Cost saved: $10,000–25,000.
  3. DAY 30 — Model Calibration Pre-check: If Pearson r < 0.35 between model predictions and held-out literature collateral sensitivity values (n=10 drug pairs), abort before wet lab phase. Cost saved: $80,000–150,000.
  4. DAY 45 — MIC Assay Reproducibility: If coefficient of variation for MIC measurements exceeds 30% across biological replicates in first strain tested, halt wet lab work and troubleshoot assay conditions. Cost saved: $30,000–60,000.
  5. DAY 60 — Early Serial Passage Signal: If at day 10 of serial passage, resistance emergence rates are statistically indistinguishable between predicted and comparator combinations (p > 0.2, interim analysis), trigger pre-specified futility analysis; abort if futility boundary crossed. Cost saved: $20,000–40,000.
  6. DAY 90 — WGS Mutation Spectrum Check: If >70% of resistance mutations in evolved populations occur at loci completely absent from model's trade-off structure, abort mechanistic validation phase and revise model assumptions. Cost saved: $15,000–30,000.
  7. DAY 120 — Generalization Test: If ROC-AUC on held-out drug pairs < 0.55 (not better than chance), abort Phase 4 and report negative result; do not proceed to external replication. Cost saved: $10,000–20,000.

Source

AegisMind Research
Need AI to work rigorously on your problems? AegisMind uses the same multi-model engine for personal and professional use. Get started